Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis.


     img2 home


The First-in-Human Phase 1b Safety Clinical Trial of CuraVac’s potential Myasthenia Gravis therapeutic vaccine succesfully meets its safety primary end points.

More information


The 5th and final meeting of the Myasterix project will take place in Brussels on the 13-14 September 2018 with the participation of the consortium and the European Commission. The meeting will be an opportunity to discuss the work conducted in the last year and throughout the project as well as plans for exploiting results. 



Coordinator Nicolas Havelange and CEO Stéphane Huberty were present at the 2018 BIO International Convenion in Boston from 4-7 June.

MYASTERIX at Flanders Vaccine Immunity for Health

Myasterix coordinator, Nicolas Havelange, presents the Myasterix project at the Immunity for Health Event organised by Flanders Vaccine on the 20th of October 2017.

MYASTERIX 4th Annual Meeting

The 4th Annual General Meeting took place in Antwerp on 21-22 September 2017. 

Start of MYASTERIX Phase 2/3 trial

We are pleased to announce the beginning of phase 2/3 of our active targeted immunotherapy for myasthenia gravis following the approval by the UZA Ethics Committee on 19 June 2017 and the Belgian and Dutch Regulatory Authorities (May 2017). Link to MYASTERIX on

Presentation of Phase 1b preliminary results now available for download

View the presentation given by Prof. Rudy Mercelis, lead investigator of the Myasterix trial at Antwerp University Hospital (UZA) at the New York Academy of Science’s 13th International Conference on Myasthenia Gravis and Related Disorders.

MYASTERIX at Bio 2017

Myasterix coordinator CuraVac will be present at BIO 2017 in San Diego, USA from 19 June to 22 June 2017.

MYASTERIX Phase 1b preliminary results presented on 16 May 2017 at New York Academy of Sciences

Prof. Rudy Mercelis, lead investigator of the Myasterix trial at Antwerp University Hospital (UZA) presented the results at the New York Academy of Science’s 13th International Conference on Myasthenia Gravis and Related Disorders in his presentation entitled A Phase 1b Clinical Trial of CV-MG01, Acetylcholine Receptor Mimetic Peptides on the 16th of May 2017 during the session on clinical trials.

For more information and press release

Update on Myasterix study: Safety report summary

The Myasterix Phase 1b study (EudraCT 2015-002880-41) is followed by a Data Review Committee which conducted a formal safety data review in August and then in December 2016.

Read more

Belgian investment & collaboration forum 22 November 2016

Nicolas Havelange and Stéphane Huberty, participated in the Belgian investment and collaboration forum on the 22nd of November 2016

Read more

MYASTERIX progress
September 2016

The 3rd MYASTERIX general meeting took place in Paris on 22-23 September 2016. It was the opportunity for the partners to present and discuss the progress made so far, at over halfway through the project, since the start of the project in 2013.

Read more



2016 BIO International Convention
June 6-9th, 2016

CURAVAC participated in BIO2016 on 6-9 June 2016

June 1st, 2016 

The Belgian and Dutch patients associations on Myasthenia Gravis organised a webinar (in Dutch) on the clinical trial of the therapeutic vaccine developed in MYASTERIX project. The webinar took place the 1st June 2016 from 18.00 to 19.00 CET. 

To view the webinar:

More info

Start of the clinical study

The phase 1b study has started at the Antwerp University Hospital (Belgium) and is currently recruiting participants.

More info


MYASTERIX is a 5-year European Collaborative Project supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme under the Grant Agreement nº 602420.

Follow us on twitter: @Myasterix1

20160923 113948